Objective To examine the association between educational level and the use of newly marketed drugs (NMD) among elderly persons. Methods We conducted a register-based, retrospective, cross-sectional study of 626,258 people aged 75-89 years who filled at least one drug prescription from August to October 2005 and who, consequently, were registered in the Swedish Prescribed Drug Register (SPDR). Data from the SPDR were record-linked to the Swedish National Inpatient Register and the Education Register. Newly marketed drugs were defined as new chemical entities that had been approved in Sweden between 2000 and 2004.
Introduction
Modern healthcare systems spend more of their financial resources on drugs for the elderly than on any other age group of the population. The aim of welfare states is to provide equity in drug treatment for all of its citizens regardless of age, sex, race, country of birth, place of residence or socioeconomic position (i.e. education, occupation and income). However, despite the establishment of a social welfare system in Sweden, there are still inequities in the medical treatment provided by the Swedish national healthcare system [1, 2] .
The limited number of studies on socioeconomic differences in drug use among the elderly, despite being limited by small sample size and different methods of data collection, have revealed the existence of a socioeconomic gradient in drug use [3] [4] [5] [6] [7] [8] . Aging populations require more and effective drug therapy, and the prescribing of expensive new drugs may place a financial burden on the healthcare system. Although many different factors may contribute to the selection of new drugs by physicians [9] [10] [11] [12] , very little is known about the influence of socioeconomic position on use of new drugs among the elderly [13] . Education is a measure of socioeconomic position (SEP), and the literature pertaining to the effect of educational attainment of elderly persons on the overall use of new drugs and individual new drugs is limited. With the establishment of the Swedish Prescribed Drug Register (SPDR), it is now possible to study socioeconomic differences in new drug use among Swedish elderly by linking the SPDR to other Swedish registers, such as the National Education Register.
The aim of this study was to investigate the association between patient educational level and the use of newly marketed drugs (NMD) among older people. We applied two measures of NMD: overall use of new drugs and the use of specific new drugs.
Method

Population and data collection
This registry-based study was conducted between August and October 2005 (3 months) and used data obtained from three national registers in Sweden: the SPDR, the national Inpatient Register and the national Education Register. The SPDR contains data on all prescriptions dispensed to the entire Swedish population (about 9 million inhabitants). The collection of data is administered by the state-owned National Corporation of Swedish Pharmacies, and the data is then transferred to the National Board of Health and Welfare (www.socialstyrelsen.se) [14] . All Swedish Pharmacies have standardized procedures to ensure high-quality data acquisition and management. The national Inpatient Register was established in 1964, and since 1987 it provides complete national coverage for each hospital admission. Diagnoses are coded according to the International Classification of Diseases (ICD). The national Education register is updated annually with information provided by Statistics Sweden on the highest level of formal education of each Swedish citizen aged 16-74 years [15] . Data from these three databases were individually linked by Swedish personal identification numbers. However, after record-linkage, all personal identification numbers were removed and the data were non-identifiable. In Sweden, the maximum quantity of prescribed drugs supplied to a patient is for a period of 90 days. Thus, the study period of 3 (August-October 2005) months approximately corresponds to current use of prescribed drugs.
The total population in Sweden aged 75 years and older was 815,282 on 30 September 2005, and 714,720 of these individuals were registered in the SPDR. It was only possible to collect information on education from the years 1990, 1997, 2000 and 2004; consequently, the data sets in the Education Register were not complete for individuals aged ≥90 years, and they were therefore excluded from our study. Individuals with missing data on type of residential area were also excluded. After the exclusion of those for whom information was lacking on the educational attainment and type of residential area (n=14,752; 2.3%), 626,258 individuals aged 75-89 years remained eligible for inclusion in this study. Thus, data on age, sex, type of residential area, comorbidity and dispensed drugs were analyzed for 626,258 elderly people.
Measurements
Dependent variables
Drug Information and categorization All dispensed drugs were classified according to the Anatomical Therapeutic Chemical (ATC) Classification System, as recommended by the World Health Organization [10] . Information included date of filling, patient identity and brand and quantity of drug prescribed. For each new drug, a reference drug class was selected; for example, all antiglaucoma preparations and miotics (S01E) were used as the reference drug class for the new drug brinzolamide (S01EC04), and all anti-dementia drugs (N06D) were used as the reference drug class for galantamine (N06DA04). Table 2 shows some relevant characteristics of NMD included in this study.
Data on newly marketed drugs
Independent variables
Demographic variables Age was categorized into three groups: 75-79 years (reference), 80-84 years and 85-89 years. Type of residential area was stratified into Stockholm, urban and rural. We used the Statistics Sweden official classification of so-called homogeneity regions for all residents, in which municipalities are classified in six homogeneity regions (H1-H6) depending on population density and the number of inhabitants in the nearest vicinity of the main city in that particular municipality. According to this classification, Sweden's capital city Stockholm and Södertälje is classified as H1, while two of the other higher density cities of Sweden, Göteborg and Malmö/Lund, are classified separately as H2. H3 includes municipalities with more than 90,000 inhabitants within a 30-km radius of the center of that municipality, and H4 includes municipalities with more than 27,000 inhabitants, but fewer than 90,000 inhabitants from the center of that municipality and also more than 300,000 inhabitants within a 100-km radius from the same centre. H5 is identical to H4 except that there are fewer than 300,000 inhabitants from the center of the municipality. Finally, H6 consists of municipalities with fewer than 27,000 inhabitants within a radius of 30-km from the center [16] . In this study, H1 was classified as Stockholm, H2-H4 were classified as urban and H5 + H6 as rural areas (reference).
Comorbidity Diagnoses from the Swedish National Inpatient Register were used to calculate a measure of comorbidity burden based on the individuals' history of all hospitalizations over the previous 7 years before measurement of drug use (1998) (1999) (2000) (2001) (2002) (2003) (2004) . The comorbidity coding was performed using the 2007 International Classification of Disease, Tenth Revision (ICD10; National Center for Health Statistics, Hyattsville, MD) in each patient record and weighting according to the method developed by Charlson et al. [17] and modified by Deyo et al. [18] The Charlson Comorbidity Index (CCI) [19] is derived by summing the weights assigned to all health problems leading to hospital admission from a predefined list of 17 medical conditions, such as cerebrovascular disease, congestive heart failure and liver disease. The CCI weighs the number and seriousness of comorbid diseases, assigning each condition a score of 1 to 6. The weights of each comorbid condition are summed to arrive at a total score. In this study, comorbidity scores were categorized as 0, 1-2, 3-4 and 5 or more.
Education Educational level was coded into three categories: low education (less than 9 years), intermediate education (9-12 years) and high education (13 or more years). The information on the highest formal education of each individual was collected from the National Education Register [15] , and to ensure the completeness of data, we assessed information from older versions of the Education Register as far back as until 1990. Due to missing data on education for most individuals aged 90 years and oldereducational level is reported annually only for individuals in the age span 16-74 years-we had to restrict the maximum age of the study population to 89 years.
Number of dispensed drugs
The total number of drugs dispensed to each individual was used as continuous variable in the analysis.
Ethics
Data security and confidentiality procedures of the Karolinska Institutet, Stockholm, were followed, and all data were non-identifiable. The study was approved by the ethical board in Stockholm, Sweden (Dnr 2006/948-31).
Statistical analysis
Multiple logistic regression was used to explore the association between educational level and new drug use. We adjusted the data for the effect of potential confounders (age, sex, type of residential area, comorbidity and number of drugs) on overall new drug use and for each new drug. The results are shown as odds ratios (OR) with 95% confidence intervals (CI). The Hosmer-Lemeshow goodnessof-fit statistic was applied to test the data's fit to the model. The software program SPSS 15.0 FOR WINDOWS (SPSS, Chicago, IL) was used for the analyses.
Results
The average age of the study population was 80.9 years, 60% were female and the majority lived in urban areas (70.6%). The CCI score was ≥1 in 28% of our elderly population. When this population was classified into low education, medium education and high education groups, the proportion with a CCI score of ≥1 was 29, 27 and 27%, respectively. The mean number of drugs dispensed was 5.8, with low-educated elderly persons using a higher number of drugs than high-educated ones. Polypharmacy was documented among 57.0% of low-educated and 51.9% of higheducated elderly (not shown in table). In total, 45,740 (7.3%) elderly persons aged 75-89 years were dispensed at least one new drug during the 3 months of the study period. The use of new drugs was more common among the younger elderly, and those with higher comorbidity index scores (Table 1) .
A total of 18 drugs met our inclusion criteria being introduced onto the Swedish market between 2000 and 2004 and having at least 350 users in our dataset. Overall, the most common new drugs were esomeprazole (1.5%), brinzolamide (0.8%) and travoprost (0.6%). The use of NMD relative to drugs in the reference class was highest for tiotropium (52.6%) and lowest for rosuvastatin (0.4%), as shown in Table 2 .
The association between education and new drug use
The low-educated elderly persons of our study cohort had the highest mean number of drugs but the lowest proportions of new drug use (Table 1) . Table 2 shows the proportions of new drug use in their respective reference drug category. The more highly educated elderly individuals used new drugs to a greater extent than their low-educated counterparts, with the exception of etoricoxib and bimatoprost, which were more commonly used by the loweducated elderly. The greatest difference in new drug use among our population based on educational level was observed for oseltamivir: 30.3 vs. 5.1% for high-educated versus low-educated individuals, respectively. In the multivariate analyses (Table 3) , the dose-response effect of education on most new drugs was clearly evident, with the exception of brinzolamide, darbepoetin alfa, etoricoxib, bimatoprost and solifenacin. Low education was associated with a lower probability of new drug use, even after adjustment for age, sex, education, type of residential area and number of drugs (Table 4 ). The association between education and new drug use remained the same after adjustment for comorbidity (adjusting for age, sex, education, type of residential area and comorbidity; results are not shown since the ORs were quite similar to those for Models 2 and 3). The number of dispensed drugs was significantly associated with the use of NMD: the likelihood of using NMD increased by 16% with each additional drug used by the elderly (OR 1.16; 95% CI 1.15-1.16). In addition, low-educated elderly women had a slightly lower probability of using new drugs than low-educated men, and type of residential area also played a role independent of education ( Table 4) .
Discussion
To the best of our knowledge, this is the first study to examine the relationship between educational level and the use of NMD in a large population of elderly individuals. The results of this large register-based study reveal that the elderly with a low level of formal education have a lower probability of being dispensed new drugs than the higheducated elderly. Similarly, the progressive increase in educational attainment of the elderly predicted a greater use of most individual NMD irrespective of patient age, sex, type of residential area, comorbidity and number of drugs used. The association between education and new drug use was especially pronounced for oseltamivir, ezetimibe and duloxetine. We found no association for brinzolamide, darbepoetin alfa, etoricoxib and bimatoprost. Our findings are in agreement with those of a Canadian population-based study on persons aged ≥65 years, which reported that newer brand-name drug prescribing modestly increased with increasing income quintile after adjusting for patient age and gender; this trend was particularly evident for the selection of newer, brand-name antipsychotics, newer generic statins and newer, brand-name ocular β-blockers [13] . A Czech study based on the general population but with an ecological design found a significantly [20] . Similarly, early users of celecoxib generally had high incomes and had paid out-of-pocket for their prescriptions [21] . There are numerous tentative explanations for these observed differences between different educational groups. One is the variability in the nature and meaning of knowledge among prescribers for different socioeconomic groups. This aspect has been explored in one paper based on a study in the UK, which stated that new drugs come into general practice based on the awareness of hospital doctors of new drugs and the assimilation and interpretation of evidential sources. In this UK-based study, the determinants of new drug prescribing were interconnected within four forms of knowledge: scientific knowledge, social knowledge, patient knowledge and experiential knowledge [22] . This variability in physicians' prescribing of new drugs relates not only to levels of acquired knowledge, but also to differences in subjective and ideological beliefs [23, 24] . One Australian study investigating the factors influencing the prescribing of new drugs among general practitioners, endocrinologists and psychiatrists found that pharmaceutical companies were the most important source of information on new drugs for these groups of healthcare providers [12] . The prescribing of new drugs is also affected by the prescriber's surrounding social system, such as location and size and type of practice [21, 25] . Contextual factors (e.g. therapeutic traditions) at healthcare centers (HCCs) may also be relevant when physicians select a new drug for the patient, as previously suggested [26] . The probability of prescribing rosuvastatin was almost fourfold higher in private clinics than in publically administrated HCCs in the Swedish county of Scania [26] .
Patient characteristics also play a key role in the prescribing of NMD. For example, increasing age, poor selfperceived health, female sex and private insurance have been linked to the high use of rofecoxib [27, 28] . In our study, we found that women were prescribed fewer NMDs than men. In contrast, in a Dutch study, female sex was associated with the higher use of a new drug (rofecoxib) [27] , while in Finland, celecoxib and rofecoxib were prescribed equally to males and females [29] . Patients' knowledge about their treatment, health and expectations are important factors in drug use. Arguably, patients with a high education may have greater access to drug information and may be more active in the patient-physician communication process. Thus, patient educational level may influence patient convenience, acceptability and a request for a new drug [30] . Of the new drugs included in our study, oseltamivir showed the strongest association with high education. Oseltamivir is an antiviral drug that is used ATC, Anatomical Therapeutic Chemical (ATC) Classification System in the treatment and prophylaxis of both Influenzavirus A and Influenzavirus B, and is more costly than the alternatives [31] . With increasing fears about the potential for a new influenza pandemic, oseltamivir has received substantial media attention. Governments, corporations and even some private individuals stockpiled the drug. One potential explanation of greater oseltamivir use among the more highly educated individuals (medical professionals, managers etc) is a better awareness of treatment alternatives and better communication skills [28] .
Except for a few counties in Sweden with a decentralized drug budget, physicians have no strong incentives for [33] . Physicians may have prescribed this drug more equally due to its similar price to the older alternative, and hence we did not observe significant differences between educational groups of elderly for this drug.
Health-related problems are more frequent among people with low SEP than among the more prosperous segment of the population [34] , and drug use and health status are closely associated [35] . In our study, however, the probability of NMD use was lower among the low-educated elderly than among their high-educated counterparts even after we controlled for comorbidity. This relation holds even when we controlled for the number of dispensed drugs in the analyses, which may be regarded as an overall measure of comorbidity [36] .
Limitations
The main strengths of this study are the large sample size, inclusion of many new drugs and our effort to measure comorbidity in the analyses. We should, however, note a number of limitations. The SPDR does not include data on over-the-counter drugs, herbal drugs and drugs used in hospitals. Further, the SPDR is incomplete with regard to drugs used in nursing homes, which may lead to an underestimation of the drug use, especially among the elderly. The measure of comorbidity is not biased by self-report, but it is limited to inpatient care. Hence, it only covers the most serious morbidity. Another limitation of the study is the restriction of the upper age limit to 89, but this was due to incomplete data on education for individuals 90 years of age and older. Hence, the analyses were based on the elderly aged 75-89 years registered in the SPDR between August and October 2005, which corresponds to 85% (626,258/736,790) of the Swedish population aged 75-89 years in September 2005. The SPDR contains information about dispensed prescribed drugs and, therefore, not all the drugs prescribed. Therefore, we do not know whether the observed variability is due to differences in the prescribing routines or in the degree to which prescriptions were filled at pharmacies. Another important limitation is that we only looked at new drugs filled at pharmacies, but we have no knowledge of patients' behavior and adherence to drugs, which may affect drug therapy. Finally, we could not determine whether the use of the new drug was linked to different health outcomes as compared to older alterative therapy. New drugs may not necessarily be better than the older alternatives. The tendency for highly educated patients to receive newer drugs may, therefore, merely act as a cost driver without actually improving patient outcomes.
Summary
The results of this study suggest that education-related inequalities in new drug use may exist even in a healthcare system that claims to ensure high degree of equity. Future research is required to explain why educational level influences the selection of new drugs and whether it has any impact on health outcomes. Also, it would be interesting to perform qualitative studies to elucidate to what extent these differences are patient-or prescriber-mediated. Our findings underline the need for continuous monitoring of drug use in different socioeconomic groups; to this end, the recently established SPDR may be very useful.
